sprite-preloader
Montag, 21.04.2014 Börsentäglich über 12.000 News von 475 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A1J84E ISIN: US00287Y1091 Ticker-Symbol: 4AB 
Aktie:
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
ABBVIE INC Chart 1 Jahr
1-Woche-Intraday-Chart
ABBVIE INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
35,15
35,35
17.04.
35,07
35,20
17.04.

Aktuelle News zu ABBVIE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
ABBVIE Aktie jetzt ab 5 Dollar handeln!

--> Artikel lesen
FrAbbVie urges U.S. court to avoid gay rights issue in HIV drug case2

--> Artikel lesen
DoEarnings Primer: What's on Deck for Celgene, AbbVie, and Gilead49

--> Artikel lesen
DoAbbVie Candidate in Pivotal Study4

--> Artikel lesen
DoThe Zacks Analyst Blog Highlights:GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics35
CHICAGO, April 17, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
--> Artikel lesen
MiApplication Now Open for Students with Cystic Fibrosis for the 2014 AbbVie CF Scholarship7
NORTH CHICAGO, Ill., April 16, 2014 /PRNewswire/ --AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship...
--> Artikel lesen
DiAbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer7
NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ --AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound...
--> Artikel lesen
DiAbbVie PT Raised to $61.00 at Jefferies Group6

--> Artikel lesen
14.04.Positive Data on AbbVie's HCV Program - Analyst Blog5

--> Artikel lesen
14.04.Positive Data on AbbVie's HCV Program2

--> Artikel lesen
14.04.Enanta Pharmaceuticals to present detailed results from AbbVie's pivotal Phase III SAPPHIRE-I study8

--> Artikel lesen
12.04.Why Delta Air Lines, AbbVie, and SanDisk Shocked Shareholders This Week19

--> Artikel lesen
12.04.AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress'14
LONDON, April 12, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver CongressTM...
--> Artikel lesen
11.04.AbbVie angles for hep C spotlight as Merck shoulders to the front9

--> Artikel lesen
11.04.AbbVie announces availability of new advanced Parkinson's treatment in Canada5

--> Artikel lesen
11.04.AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress'16
LONDON, April 11, 2014 /PRNewswire/ --AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International...
--> Artikel lesen
11.04.XFRA DIVIDEND INFORMATION - 11.04.2014 - 350
FOLGENDE WERTPAPIERE WERDEN AM 11.04.2014 EX DIVIDENDE GEHANDELT. THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 11.04.2014. INSTR EXCH ISIN INSTRUMENT NAME REF.PRC ADJUST SRT3 XFRA DE0007165631...
--> Artikel lesen
10.04.XFRA DIVIDEND INFORMATION - 11.04.2014 - 250
FOLGENDE WERTPAPIERE WERDEN AM 10.04.2014 CUM DIVIDENDE UND AM 11.04.2014 EX DIVIDENDE GEHANDELT. THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 10.04.2014. THE EX-DIVIDEND DAY WILL BE 11.04.2014. ...
--> Artikel lesen
09.04.Equities to Watch in the Health Care Sector -- Research on AbbVie, GlaxoSmithKline, AstraZeneca, and Novartis21
LONDON, April 9, 2014 /PRNewswire/ -- On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average finished 0.06%, higher at 16,256.14, and the...
--> Artikel lesen
09.04.Upcoming Results and Conference Call Schedules, New Office Facility, and Stock Price Movements-Analyst Notes on Biogen, Actavis, Bristol-Myers, AbbVie, and Baxter11
NEW YORK, April 9, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY)...
--> Artikel lesen
09.04.Why Gilead Sciences, AbbVie Inc., and Biogen Idec Are Today's 3 Worst Stocks96

--> Artikel lesen
Seite:  Weiter >>
243 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
ABBVIE INC-Investoren interessieren sich auch für diese News

Unternehmen / AktienAktienkurs%Top-Nachrichten
GILEAD SCIENCES50,94+1,88 %Gilead Sciences-Aktie: Hepatitis C-Medikament Solvadi dominiert den Markt! - Aktienanalyse
Zürich - Gilead Sciences-Aktienanalyse von Analyst Vamil Divan von der Credit Suisse: Aktienanalyst Vamil Divan von der Investmentbank Credit Suisse rechnet laut seiner Aktienanalyse für die Aktien...
--> Artikel lesen
ABBOTT LABORATORIES27,61+0,51 %Abbott Laboratories Q1 Adj. Profit Beats View, Affirms 2014 Outlook
NORTH CHICAGO (dpa-AFX) - Diversified healthcare company Abbott Laboratories (ABT) on Wednesday reported a 31 percent decline in profit for the first quarter from last year, reflecting lower...
--> Artikel lesen
NOVO NORDISK31,94+1,98 %Novo Nordisk Launches 'Cities Changing Diabetes' to Fight Urban Diabetes
BAGSVÆRD, Denmark, March 28, 2014 /PRNewswire/ --  Novo Nordisk today announces the launch of 'Cities Changing Diabetes', an ambitious new partnership programme to fight the urban diabetes challenge....
--> Artikel lesen
NOVARTIS61,17+0,26 %dpa-AFX Überblick: ANALYSTEN-EINSTUFUNGEN vom 14.04.2014: AIXTRON, ALLIANZ, ASTRAZENECA, BASF, BAYER, BEIERSDORF, BG, BMW, CLARIANT, CONTINENTAL, DAIMLER, DELTICOM, DEUTSCHE POST, ELRINGKLINGER, ENEL, ...
Ausgewählte Analysten-Einstufungen im dpa-AFX-Nachrichtendienst vom 14.04.2014 AIXTRON ZÜRICH - Die Schweizer Großbank UBS hat das Kursziel für Aixtron vor der Berichtssaison von 11,50 auf...
--> Artikel lesen
TEVA PHARMACEUTICAL INDUSTRIES36,785+1,00 %Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone; Clears Legal Hurdle for Mylan to Launch at Market Formation
PITTSBURGH, April 18, 2014 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's...
--> Artikel lesen
Lade...